Troxerutin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Troxerutin: From Chronic Venous Insufficiency to Hemoglobinopathy
One-Sentence Summary
Troxerutin (vitamin P4) is a bioflavonoid historically used to treat chronic venous insufficiency (per literature in the evidence pack; no formal original-indication record was available). The TxGNN model predicts it may be effective for Hemoglobinopathy, but this top-ranked prediction is currently supported by 0 clinical trials and 0 publications — it is a pure computational signal with no direct evidential backing.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from regulatory records; literature identifies Troxerutin’s established use as chronic venous insufficiency (CVI) |
| Predicted New Indication | Hemoglobinopathy |
| TxGNN Prediction Score | 98.33% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Denmark Market Status | Not marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (data gap). Based on known information, Troxerutin is a rutin/bioflavonoid derivative (O-(β-hydroxyethyl)-rutoside) whose established efficacy in chronic venous insufficiency relates to red-cell membrane stabilization and antioxidant activity.
The proposed rationale for hemoglobinopathy is mechanistic: Troxerutin is known to improve red blood cell membrane deformability and antioxidant capacity, which in theory could help with the red-cell fragility and oxidative stress seen in hemoglobin disorders. However, this link is purely a pharmacological inference — the TxGNN score (0.983) is a model output only, with no clinical trial or literature evidence currently identified to support it.
For context, among the other candidates surfaced for this drug, myocardial infarction reached a higher evidence tier (L3, 4 supporting publications — see the drug’s other reports), suggesting Troxerutin’s repurposing signal is stronger for cardiovascular indications than for hemoglobinopathy specifically.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Denmark Market Information
Troxerutin currently holds no marketing authorisations in Denmark (market status: not marketed; 0 licenses on record).
Safety Considerations
Please refer to the approved Summary of Product Characteristics (SmPC) for safety information. No key warnings, contraindications, or drug-drug interaction data are currently on file for this drug.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Hemoglobinopathy) is an L5, model-only signal with no clinical or preclinical evidence, and the drug is not currently marketed in Denmark. Critical safety data (label warnings and contraindications) are also missing, which blocks even a preliminary safety assessment.
To proceed, the following is needed:
- Danish/EU Summary of Product Characteristics (SmPC) data — warnings and contraindications (currently a blocking data gap)
- Confirmed mechanism of action (MOA) from DrugBank or primary literature
- Preclinical or clinical evidence specifically addressing hemoglobinopathy as an indication
- If pursuing repurposing further, consider prioritizing the myocardial infarction signal instead, which has stronger (L3) literature support
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.